北京商报讯（记者 马换换 王蔓蕾）1月5日，中国证券业协会官网发布"2026年第一批首发企业现场检查 抽查名单"，中国盐业股份有限公司（以下简称"中盐股份"）被抽中现场检查，也是唯一一家被抽中检 查的主板IPO企业。 上交所官网显示，中盐股份主板IPO于2025年12月30日获得受理，公司主要产品为食用盐、工业盐、其 他用盐等各类盐产品，同时生产味精、鸡精等盐相关产品。 本次冲击上市，中盐股份拟募集资金约16.02亿元。 ...

据了解，中盐股份主要产品为食用盐、工业盐、其他用盐等各类盐产品，同时生产味精、鸡精等盐相关 产品。本次冲击上市，公司拟募集资金约16.02亿元，扣除发行费用后，拟投资于中盐东兴盐化股份有 限公司制盐装置智能化绿色化技术升级改造项目、中盐镇江盐化有限公司100万吨/年制盐（二期）扩建 工程、中盐新干盐化有限公司20万吨/年小包装食盐智能化升级项目、数字化升级改造项目、 京津冀绿 色智能食盐储备库项目、补充流动资金。 北京商报讯（记者 马换换 王蔓蕾）12月30日晚间，上交所官网显示，中国盐业股份有限公司（以下简 称"中盐股份"）主板IPO获得受理。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、加强对公司存放于宁夏可可美生物工程有限公司存货管理问题的督促 根据公司2025年半年度报告，截至2025年6月30日，公司存放于乙方仓库中的味精及原辅料、低值易耗 品账面余额合计5,611.43万元，已计提存货跌价准备1,564.76万元，其他流动资产减值准备1,093.02万 元。 在此，本人再次督促公司严格遵守《企业内部控制基本规范》，强化内部控制，确保存货的准确性和安 全性，并尽快解决存货的产权归属问题。公司应定期盘查存货，确保存货的账面价值与实际价值相符， 并真实、准确、完整、及时地进行信息披露。 根据公司披露的信息，三家公司（宁夏可可美生物工程有限公司、宁夏玉蜜淀粉有限公司及宁夏沃野肥 业有限公司）管理人于2024年8月23日开始多次对公司存放在乙方厂区的部分原辅材料进行拍卖，截至 公司2025年半年度报告出具日，已被青铜峡市人民法院强制拍卖的原材料合计2,677.91万元。在法院查 封期间，公司对上述存放在宁夏可可美厂区的全部库存资产丧失了控制权及处置权。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大 ...

二、加强对公司存放于宁夏可可美生物工程有限公司存货管理问题的督促 根据公司2025年半年度报告，截至2025年6月30日，公司存放于乙方仓库中的味精及原辅料、低值易耗 品账面余额合计5611.43万元，已计提存货跌价准备1564.76万元，其他流动资产减值准备1093.02万元。 在此，本人再次督促公司严格遵守《企业内部控制基本规范》，强化内部控制，确保存货的准确性和安 全性，并尽快解决存货的产权归属问题。公司应定期盘查存货，确保存货的账面价值与实际价值相符， 并真实、准确、完整、及时地进行信息披露。 12月29日，ST加加发布公告称，公司董事会于2025年12月26日收到公司独立董事姚禄仕提交的《关于 加加食品集团股份有限公司关联交易赔偿等问题的督促函》（以下简称《督促函》），《督促函》具体 内容主要包括： "根据《中华人民共和国证券法》《上市公司独立董事管理办法》《上市公司治理准则》等相关法律法 规和规范性文件的规定，作为加加食品集团股份有限公司（以下简称"公司"）的独立董事，本着勤勉尽 责、独立判断的原则，现就公司关联方交易亏损未赔偿、存货损失风险等问题发表如下督促函： 一、关于杨振及其关联方宁夏可可美 ...

Core Viewpoint - The production of monosodium glutamate (MSG) in China is experiencing stable growth, with a projected output of 3.015 million tons in 2024, representing a year-on-year increase of 11.9% [1][10]. Industry Overview - MSG is primarily composed of sodium glutamate, produced through fermentation of starch or sugar by microorganisms, resulting in a product with a sodium glutamate content of 99% or higher [2][4]. - The demand for MSG is driven by the increasing quality and taste expectations of consumers, particularly in the food service and processed food sectors [1][10]. Market Demand - The apparent consumption of MSG in China is expected to reach 2.997 million tons in 2024, marking a 12.0% increase year-on-year [1][10]. - The food processing industry is the largest consumer of MSG, accounting for over 50% of the market, followed by the restaurant sector at approximately 30% [8][9]. Production and Export - China's MSG production capacity utilization rate is projected to be 84.7% in 2024 [1][10]. - In the first nine months of 2025, China exported 6,700 tons of MSG, generating an export revenue of approximately $8.72 million [1][11]. Competitive Landscape - The MSG market in China is characterized by a duopoly led by two major players: Fujian Fengfeng Group and Meihua Biological Technology Group, which dominate the industry with their extensive product offerings and global reach [11][12]. - Fujian Fengfeng Group reported a revenue of 13.96 billion yuan and a gross profit of 3.169 billion yuan in the first half of 2025, with a gross margin of 22.7% [12]. - Meihua Biological Technology Group achieved a revenue of 12.28 billion yuan in the same period, with a significant portion derived from feed amino acids and flavoring agents [12][13]. Future Trends - The MSG industry is expected to evolve towards low-sodium, natural fermentation, and composite flavor products, with a focus on customized solutions for the food processing and restaurant sectors [14]. - The growth in demand for specialized formulations for baking, pre-prepared dishes, and hot pot bases is anticipated to drive innovation and differentiation in the market [14].

近日，梅花生物发布公告称，收到了广东高院受理的由日本味之素株式会社（以下简称"味之素"）提起的侵害专利权的《民事起诉状》等文件。 截至公告发布日，上述诉讼案件尚未公开审理。梅花生物称诉讼结果存在不确定性，暂无法判断是否会对公司损益产生影响。 三季报显示，梅花生物前三季度实现营业收入182.15亿元，同比减少2.49%；实现净利润30.25亿元，同比增长51.61%。其中，第三季度实现营业收入59.35亿 元，同比减少1.71%；实现净利润12.57亿元，同比增长141.06%。 味之素认为梅花生物及其子公司通辽梅花、新疆梅花、吉林梅花在味精的生产、销售过程中，侵犯了其200580045189.5号、201480005332.7号专利权，所以 向广东高院提起诉讼。要求梅花生物及其子公司立即停止侵犯上述专利权的制造、销售、使用、许诺销售侵权行为，并销毁专用于生产被控侵权产品的设 备，以及销毁所有库存侵权产品，同时赔偿侵犯两项专利造成的经济损失共计2.6亿元。 梅花生物则在公告中提到，其与味之素为长期合作伙伴，在知识产权领域包括味精的生产技术领域有着多项合作共识，且其他多项合作至今仍然存续。 ...

Core Viewpoint - Meihua Biological and its subsidiaries are facing a lawsuit from Ajinomoto Co., Inc. for patent infringement, with potential damages amounting to 260 million yuan [2][3] - The company is also dealing with internal issues, including the imprisonment of its controlling shareholder Meng Qingshan for market manipulation, which raises concerns about governance and operational stability [5][6][7] - Despite recent operational challenges, the company has shown signs of recovery in its financial performance, although long-term revenue growth remains a concern [8][9] Legal Issues - Meihua Biological received a civil lawsuit from Ajinomoto, claiming infringement of two patents related to the production of monosodium glutamate, seeking 260 million yuan in damages [3] - Ajinomoto holds two patents: one for "Microorganisms producing L-glutamic acid" and another for "Manufacturing methods of L-amino acids" [3] - The company asserts its commitment to intellectual property rights and plans to actively defend against the lawsuit [4] Management and Governance - Meng Qingshan, the controlling shareholder, was sentenced to three years in prison (with a five-year probation) for manipulating the securities market, which raises governance concerns [5][6] - The company emphasizes that Meng has not held any position since his retirement in 2017 and that his legal issues do not impact the company's operations [7] Financial Performance - Meihua Biological experienced revenue declines in 2023 and 2024, with revenues of 27.761 billion yuan and 25.069 billion yuan, representing decreases of 0.63% and 9.69% year-on-year, respectively [8] - Net profits also fell during this period, with a decline of 27.81% and 13.85% [8] - In the first half of 2025, the company reported a revenue of 12.28 billion yuan, down 2.87%, but net profit increased by 19.96% to 1.768 billion yuan, attributed to improved sales and reduced raw material costs [8][9] Future Outlook - Despite recent improvements in profitability, industry experts caution that the company faces a "profit increase without revenue increase" situation, indicating potential long-term revenue growth challenges [9] - Meihua Biological is actively pursuing overseas acquisitions to enhance its growth prospects, with a focus on integrating these assets to drive revenue and profit growth [9]

Core Viewpoint - Meihua Biological is facing significant legal and operational challenges, including a lawsuit from Ajinomoto Co., Inc. for patent infringement with a claim of 260 million yuan, and the imprisonment of its controlling shareholder for market manipulation, which raises concerns about the company's long-term growth potential despite recent improvements in profitability [1][4][7]. Legal Issues - Meihua Biological has been sued by Ajinomoto for allegedly infringing on two patents related to the production of monosodium glutamate, with a total compensation claim of 260 million yuan [2][3]. - Ajinomoto claims ownership of two patents: one for "microorganisms producing L-glutamic acid" and another for "methods for producing L-amino acids" [2]. - Meihua Biological asserts that it has a long-standing partnership with Ajinomoto and respects intellectual property rights, indicating ongoing collaborations in technology [3]. Management and Governance - The controlling shareholder, Meng Qingshan, was sentenced to three years in prison (with a five-year probation) for manipulating the securities market, which has raised governance concerns [4][5]. - Meng Qingshan's actions were linked to a non-public offering in 2013, where he manipulated stock prices to avoid losses related to trust agreements [4][5]. - Following his retirement in 2017, Meng no longer holds any position in the company, and Meihua Biological claims that his legal issues do not affect the company's operations [6]. Financial Performance - Meihua Biological's revenue and profit have experienced fluctuations, with revenues of 27.76 billion yuan and 25.07 billion yuan in 2023 and 2024, respectively, reflecting declines of 0.63% and 9.69% year-on-year [7]. - Despite a revenue decline in the first half of 2025, net profit increased by 19.96% to 1.768 billion yuan, attributed to improved sales of key products and reduced raw material costs [7]. - The company's third-quarter report for 2025 showed a slight revenue decrease of 2.49% but a significant net profit increase of 51.61%, reaching 3.025 billion yuan, driven by cost advantages and overseas acquisitions [8]. Industry Outlook - While recent profitability improvements are noted, industry experts caution that the company faces a "profit increase without revenue growth" scenario, indicating potential long-term revenue growth challenges [8]. - Meihua Biological is actively pursuing overseas acquisitions, such as the purchase of a major Japanese amino acid company, to enhance its global presence and drive future growth [8].

Investment Rating - The investment rating for the company is "Buy" and is maintained [8] Core Views - The company is currently facing a patent infringement lawsuit initiated by Ajinomoto Co., Ltd. regarding the production and sale of monosodium glutamate, with a claim for economic damages amounting to RMB 130 million [5][12] - The company emphasizes its commitment to intellectual property rights and innovation, having completed a significant cross-border acquisition that enhances its research and development capabilities [12][12] - The company has a robust pipeline of over 400 patents and has invested over RMB 7.33 billion in R&D in 2024, maintaining a leading position in the industry [12][12] - The company is projected to achieve net profits of RMB 3.26 billion, RMB 2.55 billion, and RMB 3.08 billion for the years 2025 to 2027, respectively [12][12] Summary by Sections Event Description - The company has received a civil lawsuit from Ajinomoto Co., Ltd. for patent infringement related to the manufacturing method of L-amino acids, claiming damages of RMB 130 million [5][5] Event Commentary - The company is actively responding to the lawsuit and has stated that its operations remain normal. The outcome of the lawsuit is uncertain, and it cannot yet assess the potential impact on its financial performance [12][12] - The company has a strong focus on R&D, with a three-tier innovation system that includes basic research, pilot testing, and industrial transformation [12][12] Financial Projections - The company forecasts total revenue of RMB 24.88 billion in 2025, with a gross profit margin of approximately 20% [16] - The projected net profit for 2025 is RMB 3.26 billion, with an EPS of RMB 1.16 [16][16]

Core Viewpoint - Meihua Biotech and its subsidiaries are being sued by Japan's Ajinomoto for patent infringement related to MSG production, with a claim for damages totaling 260 million yuan [1] Company Summary - Meihua Biotech and its subsidiaries, Tongliao Meihua, Xinjiang Meihua, and Jilin Meihua, are accused of infringing on Ajinomoto's patent during the production and sale of MSG [1] - The lawsuit was filed in the Guangdong High Court, where Ajinomoto seeks to stop the infringement, destroy equipment used for producing the infringing products, and eliminate all inventory of the infringing products [1] - Meihua Biotech has stated that it maintains a normal production and operational status and will actively respond to the lawsuit, taking necessary legal measures to protect its and its shareholders' rights [1] Industry Context - Meihua Biotech has a long-standing partnership with Ajinomoto, with multiple collaborations in the field of intellectual property and MSG production technology [1] - The ongoing legal dispute highlights the competitive and litigious nature of the food additives industry, particularly in the MSG segment [1]